{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:44:19Z","timestamp":1787168659853,"version":"build-2736575974"},"reference-count":19,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.3960\/jslrt.19011","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T18:02:50Z","timestamp":1565200970000},"page":"135-139","source":"Crossref","is-referenced-by-count":5,"title":["Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system"],"prefix":"10.3960","volume":"59","author":[{"given":"Takayuki","family":"Murase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Varettoni M, Corso A, Pica G <i>et al.<\/i> Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010; 21: 325-330.","DOI":"10.1093\/annonc\/mdp329"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fassas ABT, Muwalla F, Berryman T <i>et al.<\/i> Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002; 117: 103-108.","DOI":"10.1046\/j.1365-2141.2002.03401.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Vekemans MC, Lemmens H, Delforge M <i>et al.<\/i> The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome. Br J Haematol. 2010; 149: 901-904.","DOI":"10.1111\/j.1365-2141.2010.08113.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Zhan F, Huang Y, Colla S <i>et al.<\/i> The molecular classification of multiple myeloma. Blood. 2006; 108: 2020-2028.","DOI":"10.1182\/blood-2005-11-013458"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Boyd KD, Ross FM, Chiecchio L <i>et al.<\/i>. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012; 26: 349-355.","DOI":"10.1038\/leu.2011.204"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Qiang YW, Ye S, Huang Y <i>et al.<\/i> MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. BMC Cancer. 2018; 18: 724.","DOI":"10.1186\/s12885-018-4602-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Palumbo A, Avet-Loiseau H, Oliva S <i>et al.<\/i> Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015; 33: 2863-2869.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ohbayashi K, Taniwaki M, Ninomiya M <i>et al.<\/i> A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene. Cancer Genet Cytogenet. 2003; 144: 31-35.","DOI":"10.1016\/S0165-4608(02)00862-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Narita T, Inagaki A, Kobayashi T <i>et al.<\/i> t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015; 5: e285.","DOI":"10.1038\/bcj.2015.6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Fonseca R, Bergsagel PL, Drach J <i>et al.<\/i>. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23: 2210-2221.","DOI":"10.1038\/leu.2009.174"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012; 122: 3456-3463.","DOI":"10.1172\/JCI61188"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hanamura I, Iida S, Akano Y <i>et al.<\/i> Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res. 2001; 92: 638-644.","DOI":"10.1111\/j.1349-7006.2001.tb01142.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Stewart AK, Bergsagel PL, Greipp PR <i>et al.<\/i> A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007; 21: 529-534.","DOI":"10.1038\/sj.leu.2404516"},{"key":"14","unstructured":"14 McKenna RW, Kyle RA, Kuehl WM, et al. Plasma cell myeloma. In: Swerdlow SH, Campo E, Harris NL, <i>et al<\/i>. (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, IARC, World Health Organization. 2017; pp. 243-248."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nair B, van Rhee F, Shaughnessy JD Jr <i>et al.<\/i> Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010; 115: 4168-4173.","DOI":"10.1182\/blood-2009-11-255620"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Pineda-Roman M, Zangari M, Haessler J <i>et al.<\/i> Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008; 140: 625-634.","DOI":"10.1111\/j.1365-2141.2007.06921.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Jurczyszyn A, Grzasko N, Gozzetti A <i>et al.<\/i> Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016; 91: 575-580.","DOI":"10.1002\/ajh.24351"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Katodritou E, Terpos E, Kastritis E <i>et al.<\/i> Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol. 2015; 94: 2033-2042.","DOI":"10.1007\/s00277-015-2484-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Chen CI, Masih-Khan E, Jiang H <i>et al.<\/i> Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013; 162: 483-488.","DOI":"10.1111\/bjh.12414"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/3\/59_19011\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T00:25:49Z","timestamp":1570235149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/59\/3\/59_19011\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.19011","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}